Gonadotropin-releasing hormone analogs for ovarian function protection during chemotherapy in young early breast cancer patients: The last piece of the puzzle?

SCOPUS: ed.jinfo:eu-repo/semantics/publishe

treatment of breast cancer during pregnancy regimen selection pregnancy monitoring and more

Abstract Breast cancer is uncommonly diagnosed during pregnancy but when encountered, it poses several clinical conflicts. Managing patients with gestational breast cancer should not be associated with considerable risk of morbidity provided the choice of the right drug in the right time for the right patient. Due to its relative rarity, we lack a standardized approach to manage these patients. Previous reports have suggested that women can be offered treatment strategies similar to those offered in the "non-pregnant" setup. Nevertheless, generalizing treatment decisions is too hard and treatment of these cases should be tailored according to the clinical situation. In order to ensure proper counseling of these patients, there are several key points that need to be addressed. These include timing of chemotherapy administration, the scheduling of agents, and pregnancy monitoring. In this review, we provide some guidance on how to select the chemotherapy regimen and address the feasibility and safety of administering trastuzumab during pregnancy. We also discuss some practical points on monitoring these patients during the course of pregnancy

Nanotechnology, energy and nanomedicine: a survey on scientific communications

Nanotechnology is a broad spectrum of products and processes spanning mainly human health and energy, but also agriculture, the environment and many other industries and classifications. Different attempts are made for measuring activity and investments to help inform strategy and policy decision making on the scientific, economic, health, environmental and social impacts of nanotechnology. For that reason, an overview of the current state of research communications on specific areas in connection to nanotechnology is necessary. In the present work, a survey was performed considering just the published scientific papers using online databases like Web of Science and accessing using different related terms and combinations. Data were collected since the first register from the 1970s until May 2015. The relationship between nanotechnology applied to energy transformations was established. In particular, the relationship between nuclear energy and nanotechnology is quite limited now, but it is expected to increase in the short term. Independently of the term and the combination of terms employed, a tendency is showed: nanotechnology exhibits almost exponential growth and this interdisciplinary technology can be considered as a new industrial revolution

Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients

n/

Impact of chemotherapy dose-density on radiotherapy dose-intensity after breast conserving surgery

n/

Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer.

The prognostic role of drug-induced amenorrhea (DIA) was restrospectively evaluated in 221 out of 254 consecutive premenopausal patients treated with adjuvant CMF or a CMF-containing regimen; 33 patients were eliminated because of lack of menstrual data. All patients had metastatic axillary nodes; drug regimens were: CMF x 9 courses +/- Tamoxifen (TM) and CMF x 6 courses; median age was 43 (range 26-54). Premenopausal status was defined as last normal menses within the 6 weeks preceding initiation of chemotherapy: DIA as cessation of menses for at least 3 months not later than 3 months from the end of chemotherapy. DIA occurred in 166,221 (75.1%) patients and was strictly related to the age of the patients; also, the older the patients the shorter the time required to develop DIA. At median follow up of 69 months, Mantel-Byar analysis showed a longer disease free survival (DFS) for patients who developed DIA as compared with non amenorrheic women (P less than 0.001). DIA prognostic value was independent of age, number of involved nodes, tumour size and number of CMF cycles, as assessed by the Cox model (RH 0.43, 95% C.I. 0.24-0.77), in which DIA was entered as a time dependent covariate

Inativação seletiva de esporos mantendo atividade larvicida em Bt sorovar israelensis irradiada com raios gama

Bacillus thuringiensis is used to produce biopesticides against target-insects of importance in agroindustry and human health. However, B. thuringiensis can carry the same enterotoxin-encoding genes as Bacillus cereus, suggesting a potential risk of food poisoning. The objective of this work was to study the application of gamma radiation to eliminate spores in biopesticides based on B. thuringiensis serovar israelensis in order to avoid the liberation of these spores in the environment. The application of 20 kGy of radiation ensures total inactivation of the spores in the insecticide without changing the larvicidal activity. Results showed that it is possible to develop formulations containing B. thuringiensis serovar israelensis (IPS-82) eliminating viable spores with gamma radiation without affecting the larvicidal activity. Irradiated formulations would be safer for the environment and humans since the elimination of viable spores abolishes the pathogenic potential of B. thuringiensis strains.Keywords: biopesticides, gamma radiation, larvicidal insecticides.Bacillus thuringiensis é usado na produção de biopesticidas contra insetos-alvo de importância na agroindústria e na saúde pública. Contudo, B. thuringiensis pode apresentar os mesmos genes codificadores de enterotoxinas presentes em Bacillus cereus, sugerindo a possível existência de risco para intoxicação alimentar. O objetivo deste trabalho foi estudar a aplicação de radiação gama para a eliminação de esporos em preparações de biopesticidas de B. thuringiensis sorovar israelensis de forma a se evitar a liberação de esporos viáveis no ambiente. Observou-se que a aplicação de 20 kGy garante a inativação total dos esporos no inseticida sem que haja mudança na atividade larvicida. Os resultados obtidos demonstram que é possível desenvolver formulações contendo B. thuringiensis sorovar israelensis (IPS-82) eliminando-se esporos viáveis sem alteração da atividade larvicida. As formulações irradiadas seriam mais seguras para o meio-ambiente e para seres humanos uma vez que a eliminação dos esporos viáveis neutraliza o potencial patogênico de cepas de B. thuringiensis.Palavras-chave: biopesticidas, radiação gama, inseticidas larvicidas

Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)

Background: First-line chemotherapy regimens suitable for elderly advanced breast cancer patients are still not defined. Patients and methods: Women with stage III or IV breast cancer aged >_70 years were enrolled in a phase II study aimed to evaluate both activity and toxicity of weekly paclitaxel. Among 46 planned patients, at least 18 responses and not more than seven unacceptable toxic events are required for a favourable conclusion. Paclitaxel 80 mg/m2 was administered weekly for 3 weeks every 28 days. Results: Unacceptable toxicity occurred in seven out of 46 patients evaluated for toxicity [15.2%; exact 95% confidence interval (CI) 7.6% to 28.2%] and was represented by one case of febrile neutropenia, one case of severe allergic reaction and five cases of cardiac toxicity. Among 41 patients evaluated for response, a complete response occurred in two (4.9%) patients and a partial response in 20 (48.8%), with an overall response rate of 53.7% (exact 95% CI 38.7% to 67.9%). The median progression-free survival was 9.7 months (95% CI 8.5\u201318.7) and median survival was 35.8 months (95% CI 19\u2013not defined). Conclusions: Weekly paclitaxel is highly active in elderly advanced breast cancer patients. Data on cardiovascular complications, however, indicate the need for a careful monitoring of cardiac function before and during chemotherap

Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis

Background: The role of platinum-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients is highly controversial and it is not endorsed by current guidelines. Our meta-analysis aimed to better elucidate its activity, efficacy and safety. Material and methods: A systematic search of Medline, Web of Science and conferences proceedings up to 30 October 2017 was carried out to identify randomized controlled trials (RCTs) investigating platinum-based versus platinum-free neoadjuvant chemotherapy in TNBC patients. Using the fixed and random effects models, pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CI) were calculated for pathological complete response (pCR, defined as ypT0/is pN0), event-free survival (EFS), overall survival (OS) and grade 3 and 4 adverse events (AEs: neutropenia, anemia, thrombocytopenia and neuropathy). Results: Nine RCTs (N \ubc 2109) were included. Overall, platinum-based neoadjuvant chemotherapy significantly increased pCR rate from 37.0% to 52.1% (OR 1.96, 95% CI 1.46\u20132.62, P < 0.001). Platinum-based neoadjuvant chemotherapy remained significantly associated with increased pCR rate also after restricting the analysis to the three RCTs (N \ubc 611) that used the same standard regimen in both groups of weekly paclitaxel (with or without carboplatin) followed by anthracycline and cyclophosphamide (OR 2.53, 95% CI 1.37\u20134.66, P \ubc 0.003). Conversely, among the 96 BRCA-mutated patients included in two RCTs, the addition of carboplatin was not associated with significantly increased pCR rate (OR 1.17, 95% CI 0.51\u20132.67, P \ubc 0.711). Two RCTs (N \ubc 748) reported survival outcomes: no significant difference in EFS (HR 0.72, 95% CI 0.49\u20131.06, P \ubc 0.094) and OS (HR 0.86, 95% CI 0.46\u20131.63, P \ubc 0.651) was observed. A significant higher risk of grade 3 and 4 hematological AEs, with no increased risk of grade 3 and 4 neuropathy was observed with platinum-based neoadjuvant chemotherapy. Conclusion: In TNBC patients, platinum-based neoadjuvant chemotherapy is associated with significantly increased pCR rates at the cost of worse hematological toxicities. Platinum-based neoadjuvant chemotherapy may be considered an option in TNBC patients